HighTide Therapeutics, Inc. (2511) has appointed Dr. Filip Surmont as Chief Medical Officer to drive the global strategy, clinical development, and medical affairs of its cardiovascular-kidney-metabolic (CKM) diseases portfolio. The appointment is intended to accelerate clinical programs and heighten the value of the company’s core pipeline.

Dr. Surmont brings over 30 years of experience in healthcare and pharmaceuticals, including 18 years in senior roles at major multinational companies and 16 years in clinical practice. He has played significant roles in the advancement of blockbuster medications and large-scale clinical transformations, including efforts in cardiovascular, metabolic, and renal treatments. He has also authored numerous peer-reviewed articles in high-impact medical journals.

According to the announcement, Dr. Surmont’s appointment reflects HighTide Therapeutics’ continued commitment to building a strong leadership team to further develop and expand its CKM disease-focused programs.